Cardiac safety strategies

Expert Opinion on Drug Safety

Volumn 5, Issue 2, 2006, Pages 329-333

  Hanton, Gilles ^a   Tilbury, Lorraine ^a  

^a PFIZER INC   (United States)

Author keywords

Arrhythmia; ICH E14 guideline; ICH S7 guideline; QT interval; T wave

Indexed keywords

ASTEMIZOLE; ATENOLOL; DRUG; FUROSEMIDE; GLYCERYL TRINITRATE; ISOPRENALINE; MOXIFLOXACIN; POTASSIUM CHANNEL HERG;

ARRHYTHMOGENESIS; AUTONOMIC NERVOUS SYSTEM; BIOMEDICINE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEUROPATHY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INDUSTRY; DRUG SAFETY; DRUG SCREENING; HEART ARRHYTHMIA; HEART RATE VARIABILITY; HUMAN; HYPOKALEMIA; NONHUMAN; ORGANIZATION; OSTEOARTHRITIS; PRACTICE GUIDELINE; PREDICTION; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RODENT; SCREENING TEST; T WAVE; TELEMETRY; TORSADE DES POINTES; UNIVERSITY; CHEMICALLY INDUCED DISORDER; DRUG THERAPY; LONG QT SYNDROME; PUBLIC RELATIONS; SAFETY;

DRUG INDUSTRY; DRUG THERAPY; HUMANS; INTERPROFESSIONAL RELATIONS; LONG QT SYNDROME; PRACTICE GUIDELINES; RISK ASSESSMENT; SAFETY;

EID: 33644888290     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.2.329     Document Type: Conference Paper

References (9)

1. SHAH RR: Drugs, QTc internal prolongation and final ICH E14 guideline. An important milestone with challenges ahead. Drug Safety (2005) 28(11):1009-1028.
2. CAVERO I, CRUMB W: ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opin. Drug Saf. (2005) 4(3):509-530.
3. BELARDINELLI L, ANTZELEVITCH C, VOS MA: Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol. Sci. (2003) 24(12):619-625.
4. HONDECHEM LM, HOFFMANN P: Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: Importance of triangulation, reverse use dependence, and instability. J. Cardiovasc. Pharmacol. (2003) 41(1):14-24.
5. ANTZELEVITCH C, SHIMIZU W: Cellular mechanisms underlying the long QT syndrome. Curr. Opin. Cardiol. (2002) 17:43-51.
6. HONDEGHEM LM, CARLSSON L. DUKER C: Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation (2001) 103(15):2004-2013.
7. YAN G-X, ANTZELEVITCH C: Cellular basis for the normal T wave and the clectrocardiogrphic manifestations of the long-QT syndrome. Circulation (1998) 98(18):1928-1936.
8. GALEANO EJ, YOSHIDA A, OHNISHI Y et al.: Comparative usefulness of beat-to-beat QT dispersion and QT interval fluctuations for identifying patients with organic heart disease at risk for ventricular arrhythmias. Circ. J. (2003) 67(2):125-128.
9. MALIK M, BATCHAVAROV VN: Measurement, interpretation and clinical potential of QT dispersion. J. Am. Coll. Cardiol. (2000) 36(6):1749-1766.